new BindingDB logo
myBDB logout

118 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28613895 66 A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose.EBI Eli Lilly and Company
27966948 86 Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.EBI Pharmaceutical Company Limited
28337319 28 Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization.EBI Universit£ di Pisa
27825552 152 Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.EBI Takeda Pharmaceutical Company Limited
27452283 241 Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.EBI Jadavpur University
26871660 68 Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.EBI San Raffaele Scientific Institute
26653735 81 Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.EBI Pfizer Inc.
26753813 22 Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.EBI University of Minnesota
26263024 47 N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.EBI Universit£ di Pisa
26192023 71 SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.EBI £Florida Atlantic University
25264600 64 Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.EBI Takeda Pharmaceutical Company Limited
25415648 63 Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.EBI Eli Lilly and Company
25265401 38 Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.EBI Universidad CEU San Pablo
25192810 66 Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1 binding site.EBI Takeda Pharmaceutical Company Ltd
24316668 34 Discovery of a benzimidazole series of ADAMTS-5 (aggrecanase-2) inhibitors by scaffold hopping.EBI Asahi Kasei Pharma Corporation
24071448 24 Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.EBI Universit£ degli Studi 'Aldo Moro' di Bari
24028490 46 O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.EBI University of Notre Dame
24044434 71 Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.EBI Università di Pisa
23999043 1 Design and synthesis of MMP inhibitors with appended fluorescent tags for imaging and visualization of matrix metalloproteinase enzymes.EBI Mallinckrodt Pharmaceuticals
23810497 51 Hydantoin based inhibitors of MMP13--discovery of AZD6605.EBI AstraZeneca
23631440 44 Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.EBI Florida State University
23453070 42 A series of thiazole derivatives bearing thiazolidin-4-one as non-competitive ADAMTS-5 (aggrecanase-2) inhibitors.EBI Asahi Kasei Pharma Corporation
23376997 53 Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.EBI Universit£ di Pisa
23287054 46 Sulphonamides: Deserving class as MMP inhibitors?EBI Indian Institute of Technology (BHU)
23458498 24 Synthesis and preliminary evaluation in tumor bearing mice of new (18)F-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.EBI Universit£ del Piemonte Orientale"Amedeo Avogadro"
17275314 701 Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.EBI Pomona College
21669521 44 Selective non zinc binding inhibitors of MMP13.EBI AstraZeneca
21780776 40 Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.EBI Wroclaw University of Technology
21413800 56 A one-pot synthesis and biological activity of ageladine A and analogues.EBI Macquarie University
22737278 44 Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.EBI TBA
22175799 22 Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.EBI Alantos Pharmaceuticals AG
22342144 72 Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.EBI PanThera Biopharma, LLC
19715320 87 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI University of Florida
18251495 69 Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI Pfizer Inc.
18061445 103 Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Research and Development
17127067 21 Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.EBI Instituto Superior T£cnico
15713379 40 N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.EBI Universit£ degli Studi di Pisa
15582436 7 N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.EBI Sejong University
12773042 195 Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.EBI Wyeth Research
11472217 157 Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.EBI DuPont Pharmaceuticals Company
15177439 96 Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.EBI Pfizer Inc.
22386984 67 In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.EBI Colosseum Combinatorial Chemistry Centre for Technology (C4T SCarl)
22175825 19 Potent inhibitors of LpxC for the treatment of Gram-negative infections.EBI Pfizer Inc.
22153941 140 Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.EBI AstraZeneca
22017539 75 Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.EBI Boehringer Ingelheim Pharmaceuticals Inc
22017477 35 Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.EBI Instituto Superior T£cnico
22088955 33 Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.EBI Universit£ di Napoli Federico II Via D. Montesano 49
21548582 57 Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.EBI University of Illinois at Chicago
21866961 28 Selective water-soluble gelatinase inhibitor prodrugs.EBI University of Notre Dame
20726512 282 Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.EBI Pfizer Inc.
21514700 56 Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.EBI Universit£ di Pisa
21536437 219 Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.EBI AstraZeneca
20638281 56 Structure and activity relationships of tartrate-based TACE inhibitors.EBI Merck Research Laboratories
21507637 102 MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.EBI Pfizer Inc.
21493063 67 MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.EBI Pfizer Inc.
21458257 87 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.EBI Merck Research Laboratories
21417219 179 Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.EBI Central Pharmaceutical Research Institute
21300546 129 The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.EBI AstraZeneca
24900296 38 Sulfonate-Containing Thiiranes as Selective Gelatinase InhibitorsEBI TBA
20529685 70 MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.EBI Pfizer Research& Development
20529684 112 Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.EBI Pfizer Research& Development
20180536 128 Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.EBI Universit£ di Pisa
20172725 49 Discovery and SAR of hydantoin TACE inhibitors.EBI Merck Research Laboratories
20022498 71 The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.EBI Schering-Plough Research Institute Cambridge
20005097 58 Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI Pfizer Inc.
19908842 84 Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.EBI National Human Genome Research Institute
19703773 63 The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.EBI GSK Medicines Research Centre
19775099 184 Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.EBI Universit£ di Pisa
19625186 59 3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.EBI Wyeth Research
19524436 27 Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group.EBI University of Shizuoka and Global COE Program
19725580 93 Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.EBI Wyeth Research
19606871 124 N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.EBI Universit£ di Pisa
18835710 69 Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.EBI Schering Plough Research Institute
19410464 71 Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.EBI Wyeth Research
19329309 49 Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: a class of potent aggrecanase-1 inhibitors.EBI Wyeth Research
19053764 101 Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.EBI Instituto Superior Técnico
18945617 50 Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.EBI Pfizer Global Research and Development
18790648 317 Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.EBI University of Athens
18782669 90 Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.EBI Université de Reims-Champagne-Ardenne
17623656 34 Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.EBI Pfizer Global Research and Development
18029177 57 A novel series of highly selective inhibitors of MMP-3.EBI Pfizer Global Research and Development
17591762 102 Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.EBI Pfizer Global Research and Development
17531482 67 Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.EBI Wyeth Research
17512742 32 Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.EBI Université de Reims-Champagne-Ardenne
17276676 112 A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17088065 106 alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.EBI Università "G. d'Annunzio"
17064892 123 Identification of potent and selective TACE inhibitors via the S1 pocket.EBI Wyeth Research
16723229 108 Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.EBI Wyeth Research
16516466 175 Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16473009 23 Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16420030 38 Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.EBI Chinese Academy of Sciences
16392792 29 Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.EBI Aventis Pharma Deutschland GmbH
16153831 87 Synthesis and SAR of highly selective MMP-13 inhibitors.EBI Wyeth Research
16005220 52 Identification of potent and selective MMP-13 inhibitors.EBI Wyeth Research
15953722 56 Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.EBI Pfizer Global Research and Development
15837315 13 A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.EBI Università degli Studi di Pisa
15780611 74 Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.EBI Pfizer Global Research and Development
15324896 71 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.EBI Pfizer Global Research and Development
14711305 26 Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.EBI University of Athens
14684295 109 Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.EBI Chinese Academy of Sciences
12877590 28 A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.EBI Pfizer Global Research and Development
12408705 73 Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.EBI Bristol-Myers Squibb Company
11958997 53 Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.EBI University of Bielefeld
11585440 76 Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.EBI DuPont Pharmaceuticals Company
11563922 147 Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.EBI Universität Bielefeld
11229774 40 Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).EBI Pfizer Global Research and Development
11229773 73 Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.EBI Pfizer Global Research and Development
10411481 144 Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.EBI CEA
9548812 67 Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.EBI Kanebo Ltd.
28558971 38 Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors.EBI Merck& Co.
28653849 67 Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.EBI Department of Chemistry, Scripps Florida , 130 Scripps Way, Jupiter, Florida 33458, United States.